<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02095964</url>
  </required_header>
  <id_info>
    <org_study_id>BYIEAH-281</org_study_id>
    <nct_id>NCT02095964</nct_id>
  </id_info>
  <brief_title>HDL-C in Cardiac Syndrome X</brief_title>
  <acronym>HIRICS-X</acronym>
  <official_title>HDL-Cholesterol is Inversely Related With Inflammation in Cardiac Syndrome X</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bursa Yüksek İhtisas Education and Research Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bursa Yüksek İhtisas Education and Research Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      High density lipoprotein cholesterol (HDL-C) is in the centrum of the process of reverse&#xD;
      cholesterol transport from peripheral cells to the liver[10]. HDL-C promotes endothelial&#xD;
      generation of nitric oxide (NO) and improves endothelial function and arterial&#xD;
      vasoreactivity[11]. In several studies, lower HDL-C level was reported to be associated with&#xD;
      increased coronary artery disease (CAD) risk[12-14]. HDL-C also has anti- inflammatory and&#xD;
      anti-oxidant activities[15,16]. Concerning anti-inflammatory activity, HDL-C inhibits the&#xD;
      activation of monocytes/macrophages and neutrophils[17,18] and inhibits the expression of&#xD;
      endothelial adhesion molecules, such as vascular cell adhesion molecule-1 (VCAM-1) and&#xD;
      E-selectin[15].&#xD;
&#xD;
      In this study we aimed to investigate the relation of HDL-C level with systemic inflammatory&#xD;
      markers in patients with cardiac syndrome X (CSX).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2012</start_date>
  <completion_date type="Actual">January 2014</completion_date>
  <primary_completion_date type="Actual">December 2013</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Crossover</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>HDL-Cholesterol</measure>
    <time_frame>6 MONTHS</time_frame>
    <description>HDL-Cholesterol &lt;40 mg/dL(male) / &lt; 50mg/dL(female) ==&gt; low HDL-C</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cardiac Syndrome X</measure>
    <time_frame>6 months</time_frame>
    <description>Patients who have typical anginal chest pain+ischaemic findings at exercise stress test/myocardial scintigraphy + normal epicardial coronaries at coronary angiography ==&gt; Cardiac syndrome X</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Inflammation</measure>
    <time_frame>6 months</time_frame>
    <description>CRP &gt; 2,98 mg/dL ==&gt; systemic inflammation</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">710</enrollment>
  <condition>Cardiovascular Diseases</condition>
  <condition>Heart Diseases</condition>
  <condition>Myocardial Ischaemia</condition>
  <condition>Unstable Angina</condition>
  <condition>Microvascular Angina</condition>
  <arm_group>
    <arm_group_label>Cardiac Syndrome X</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Group</arm_group_label>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        CSX was defined as typical chest pain during rest or effort, abnormal test result for&#xD;
        exercise ECG and myocardial perfusion scintigraphy, and the presence of angiographically&#xD;
        normal epicardial coronary arteries. Control group was selected from volunteers presented&#xD;
        to our hospital with the complaint of typical anginal chest pain who had no ischemia on&#xD;
        myocardial perfusion scintigraphy or during the treadmill exercise test, had similar risk&#xD;
        profile with the patients (diabetes, hypertension, age, gender) and had normal epicardial&#xD;
        coronaries at coronary angiography.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Must be able to get exercise stress test&#xD;
&#xD;
          -  Must be able to have coronary angiography&#xD;
&#xD;
          -  Clinical diagnosis of typical anginaduring rest or effort&#xD;
&#xD;
          -  Abnormal test result for exercise ECG or myocardial perfusion scintigraphy&#xD;
&#xD;
          -  Must have of angiographically normal epicardial coronary arteries&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with valvular heart disease (mitral stenosis and moderate to severe mitral&#xD;
             regurgitation&#xD;
&#xD;
          -  Patients with moderate to severe aortic stenosis and regurgitation including mitral&#xD;
             annular calcification)&#xD;
&#xD;
          -  Patients with heart failure (left ventricular ejection fraction &lt;50%)&#xD;
&#xD;
          -  Patients with congenital heart disease, cardiomyopathy, left ventricular hypertrophy,&#xD;
             right ventricular hypertrophy&#xD;
&#xD;
          -  Patients with cardiac surgery&#xD;
&#xD;
          -  Patients with thyroid disease&#xD;
&#xD;
          -  Patients with anemia&#xD;
&#xD;
          -  Patients with pulmonary diseases&#xD;
&#xD;
          -  Patients with infectious diseases (locally or systemic)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>47 Years</minimum_age>
    <maximum_age>58 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>March 2014</verification_date>
  <study_first_submitted>March 17, 2014</study_first_submitted>
  <study_first_submitted_qc>March 24, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 26, 2014</study_first_posted>
  <last_update_submitted>March 24, 2014</last_update_submitted>
  <last_update_submitted_qc>March 24, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 26, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>cardiac syndrome X</keyword>
  <keyword>inflammation</keyword>
  <keyword>dyslipidemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Angina Pectoris</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Angina, Unstable</mesh_term>
    <mesh_term>Microvascular Angina</mesh_term>
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

